Celcuity Heads Into Launch-Defining Print With Bears Still Heavily Positioned

CELC enters its Q2 earnings release today carrying one of the most contested short books in small-cap biotech — and a month of selling that has left the stock down 17% to $86.60.

Short sellers remain a dominant force. At 21.7% of the free float, short interest is elevated by any measure, even after declining roughly 12% over the past week as bears trimmed positions. The ORTEX short score sits at 72.4, near its recent range high, signalling that the overall short-selling configuration — combining position size, borrow demand and price pressure — remains firmly bearish in character. One counterpoint: the borrow market itself has loosened considerably. Availability has climbed to 149% of outstanding short interest, well above the 52-week tightest reading of 69% hit in mid-July, and cost to borrow has eased to just 0.47%. That combination means new shorts face little friction, but there is equally no mechanical squeeze pressure building.

Options positioning adds a layer of caution without tipping into outright alarm. The put/call ratio has nudged up to 0.995, modestly above its 20-day average of 0.952, but the z-score of 0.81 falls well short of the defensive extremes the stock has reached — a 52-week high PCR of 2.78 makes the current reading look restrained by comparison. The cleaner signal is the price trend itself: the stock fell 6% on Thursday alone and has shed 7% on the week, suggesting sellers are already active ahead of the print rather than waiting to react.

The bull and bear cases map directly onto a single question: whether Revtorpyk (gedatolisib) can translate FDA approval in ER+/HER2- breast cancer into real commercial traction. Bulls point to a differentiated mechanism and strong clinical data in a large addressable market, with analysts maintaining constructive ratings across the Street — Citizens lifted its target to $177 and HC Wainwright raised to $155 in mid-July, both maintaining positive ratings. The consensus price target of $161 implies roughly 86% upside to Thursday's close. Bears counter with a harder argument: mandatory genotyping requirements, a safety profile that demands monitoring, and the difficulty of executing a first commercial launch from a standing start. That skepticism is why, even with a $161 Street target, over a fifth of the float remains short. The institutional register also bears watching: Baker Bros. Advisors — previously the largest holder at nearly 10% of shares — sold over $317 million worth of stock in July alone, trimming its position materially at prices well above today's level.

Tonight's print is therefore less a test of the science and more a test of early commercial execution — prescription ramp, payer dynamics and whether the launch curve for Revtorpyk is tracking ahead of, in line with, or behind what an optimistic Street has already priced in.